Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01009346 · ClinicalTrials.gov registry record · Phase 1
RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN
A Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01009346 is a Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 9 participants.
The verdict
NCT01009346, a Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN). Secondary Objectives 1.To assess the toxicity of RAD001 in combination with weekly cetuximab and cisplatin on days 1 and 8 of each 28 day cycle in patients with recurrent or metastatic SCCHN,
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Cetuximab
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01009346
The ClinicalTrials.gov registry entry for NCT01009346 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Carboplatin is the first listed.
NCT01009346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01009346 about?
NCT01009346 is a clinical study titled "RAD001 in Combination With Cetuximab and Cisplatin in Recurrent and Metastatic SCCHN". 1.Phase I: To estimate the Maximum Tolerated Dose (MTD) of RAD001 in combination with cetuximab and cisplatin for treatment of metastatic squamous cell cancer of the head and neck (SCCHN). Secondary Objectives 1.To assess the toxicity of RAD001 in combination with weekly cetuximab and cisplatin on...
What is the current status of trial NCT01009346?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2009-10. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01009346?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Cetuximab (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT01009346?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.